Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 6/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
| ▸ | CASP2 | P42575 | 1/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23945685 | 0.89 | SMN1; SMN2 (0.44) | EPHX2CYP2C19ALDH1A1HPGDFAAH | |
| SCHEMBL21107578 | 0.87 | MEN1 (0.44) | ALDH1A1HPGDSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL25881862 | 0.85 | MEN1 (0.39) | EPHX2CYP2C19ALDH1A1HPGDFAAH | |
| SCHEMBL22790738 | 0.84 | MEN1 (0.52) | EPHX2CYP2C19FAAHKMT2ATSHR | |
| SCHEMBL22856128 | 0.82 | MEN1 (0.53) | EPHX2CYP2C19FAAHKMT2ARECQL | |
| SCHEMBL24673572 | 0.82 | CASP2 (0.54) | EPHX2FAAHTSHRRECQLCASP2 | |
| SCHEMBL23945522 | 0.81 | EPHX2 (0.36) | EPHX2CYP2C19ALDH1A1FAAHSMN1; SMN2 | |
| SCHEMBL21106780 | 0.79 | CYP2C19 (0.41) | EPHX2CYP2C19ALDH1A1KMT2ATSHR | |
| SCHEMBL23945272 | 0.79 | KDM4E (0.53) | EPHX2CYP2C19FAAHCES2 | |
| SCHEMBL18459570 | 0.79 | CASP2 (0.41) | EPHX2ALDH1A1HPGDFAAHSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230190940-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20210228562-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230190940-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | EPHX2 1890/4885CYP2C19 3990/4885ALDH1A1 2776/4885 |
| US-20210228562-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | EPHX2 1890/4885CYP2C19 3990/4885ALDH1A1 2776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.